CE
Cell Bio Human Tech Co., Ltd
318160 | KO
Overview
Corporate Details
- ISIN(s):
- KR7318160009
- LEI:
- Country:
- South Korea
- Address:
- 경기도 안양시 동안구 시민대로 401 대륭테크노타운15차 제2001호,제2101호, 안양시
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-19 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 31.8 KB | ||
| 2025-09-19 00:00 |
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
|
Korean | 53.0 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
|
Korean | 28.2 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
|
Korean | 28.2 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
신탁계약해지결과보고서
|
Korean | 20.6 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
신탁계약해지결과보고서
|
Korean | 22.3 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
[기재정정]주요사항보고서(자기주식취득신탁계약해지결정)
|
Korean | 31.1 KB | ||
| 2025-08-28 00:00 |
Interim / Quarterly Report
[기재정정]반기보고서 (2025.06)
|
Korean | 1.2 MB | ||
| 2025-08-18 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.2 MB | ||
| 2025-06-02 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.0 KB | ||
| 2025-05-27 00:00 |
Major Shareholding Notification
신탁계약에의한취득상황보고서
|
Korean | 52.6 KB | ||
| 2025-05-27 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-05-14 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-04-02 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.4 KB |
Automate Your Workflow. Get a real-time feed of all Cell Bio Human Tech Co., Ltd filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Cell Bio Human Tech Co., Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cell Bio Human Tech Co., Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Discovering novel gene editing tools from nature for curative genetic medicines.
United States of America
MGX
United States of America
MGX
AI-powered biotherapeutics firm offering end-to-end antibody discovery and engineering services.
United States of America
HYFT
United States of America
HYFT
Licenses patented helmet technology to reduce rotational impact injuries in sports and construction.
Sweden
MIPS
Sweden
MIPS
Japan
3636
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden
MODTX
Sweden
MODTX
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland
MOC
Poland
MOC
Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.
United States of America
MNPR
United States of America
MNPR
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
Ireland
MURA
Ireland
MURA
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom
N4P
United Kingdom
N4P
Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.
Poland
NNG
Poland
NNG